Full-Time
Senior Director
Business Development
Posted on 9/11/2025
Endpoint Clinical
501-1,000 employees
Interactive response technology for clinical trials
Compensation Overview
$120k - $150k/yr
Remote in USA
Remote
 Business & Strategy (1) |
|---|
- Bachelor's degree or equivalent and/or appropriate experience
- 6-9 years RTSM/IRT or pharmaceutical services related sales experience
- Proven track record of success in Business to Business Software sales
- Ability to understand and communicate technical concepts
- Proven ability to work independently as well as in a sales team environment
- Organized with methodical approach for prospecting
- Excellent oral and written communication skills
- Responsible for selling clinical trials software (RTSM/IRT) to pharmaceutical and biotech companies
- Achieving company sales goals
- Establish and maintain client relationships while prospecting for new opportunities
- Educate customers on the value of a new software platform
- Maintain accurate records and log all activities in our sales force automation system
- Communicate weekly activities and coordinate sales pipeline with sales leadership
- Prepare and deliver presentations to clients about the endpoint platform
- Generate quotes and proposals using available templates
- Participate in various trade shows and conferences
- Assist in the creation of new sales plans and strategies
- Demonstrate efficient and accurate completion of all responsibilities
- Winning customer awards for new business
Endpoint Clinical provides interactive response technology (IRT) software for clinical trials, helping life sciences companies manage drug supply, patient randomization, and visit scheduling. Its platform coordinates these trial operations through a user-friendly system that can be set up, integrated with other trial management tools, and backed by ongoing services and support. The company differentiates itself through an emphasis on ease of use, strong integration with other systems, and comprehensive customer support, including collaborations with partners like THREAD and Berlinger to offer integrated solutions. Its primary goal is to help sponsors, CROs, and academic institutions run clinical trials more efficiently, with improved transparency and regulatory compliance.
Company Size
501-1,000
Company Stage
Debt Financing
Total Funding
$1.7M
Headquarters
San Francisco, California
Founded
2009
Simplify's Take
What believers are saying
- Sri Srivatsan appointed CEO March 2025 to accelerate innovation and sales.
- Liz Troll joins as VP Quality with 40 years experience enhancing compliance.
- $126 million revenue fuels global expansion with 600 employees.
What critics are saying
- Medidata undercuts pricing, capturing 35% market share in 6-12 months.
- Oracle's AI supply chain outpaces Elosity, losing adaptive trial contracts in 12-18 months.
- FDA March 2026 guidance exposes elo non-compliance, triggering audits in 3-6 months.
What makes Endpoint Clinical unique
- Elosity R3 launches AI elo for natural language RTSM queries while preserving blinding.
- Proprietary PULSE platform enables study builds in four weeks versus industry 8-16 weeks.
- Exclusive RTSM focus supports 800 active studies across 90 countries.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Company News
Endpoint Clinical has launched Elosity R3, a major update to its Randomisation and Trial Supply Management platform. The release introduces enhanced clinical supply operations tools, including central pharmacy management, flexible sourcing strategies and patient rollover capabilities across studies. The update expands the platform's AI capabilities through elo, which enables clinical teams to interact with RTSM and supply data using natural language whilst maintaining study blinding and regulatory compliance. Elosity R3 aims to support increasingly complex global and adaptive trials by strengthening how teams plan, manage and monitor clinical supply operations. Built on cloud-based architecture, the platform enables connectivity across clinical and enterprise systems, providing end-to-end visibility. The release is now available to sponsors and contract research organisations worldwide.
Isa Grimes represents Endpoint Clinical at NYC Awards Night. Published. March 31, 2026 At this year's NYC Awards Night, The Healthcare Technology Repo were pleased to welcome leaders across healthcare and technology who are driving innovation in patient care and clinical outcomes. Among those in attendance was Isa Grimes, VP of Global Marketing at Endpoint Clinical, a company focused on advancing clinical trial technology through interactive response systems and digital solutions. Endpoint Clinical provides interactive response technology (IRT/RTSM) that supports patient randomization and clinical trial supply management, enabling sponsors and CROs to manage dosing, drug distribution, and inventory across complex, global studies. Its platform is designed to bring greater control and visibility to trial operations, helping teams navigate protocol complexity and execute studies more efficiently. Isa brings over 20 years of experience across digital, brand, and performance marketing, with a strong track record of leading global teams and driving strategic growth. At Endpoint Clinical, he builds data-driven go-to-market strategies that increase pipeline contribution and support revenue growth, while enhancing the company's visibility and differentiation within the eClinical space. It was a pleasure having Isa join The Healthcare Technology Repo in New York and represent Endpoint Clinical at this year's event. Picture: Isa Grimes at NYC Awards Night.
Endpoint Clinical named a Leader in Everest Group's 2025 Life Sciences RTSM Products PEAK Matrix(R) Assessment. News provided by. Dec 01, 2025, 17:09 ET RALEIGH, N.C., Dec. 1, 2025 /PRNewswire/ - Endpoint Clinical has been recognized as a Leader in the 2025 Everest Group Life Sciences Randomization and Trial Supply Management (RTSM) Products PEAK Matrix(R) Assessment. This distinction reflects Endpoint Clinical's commitment to advancing clinical research through innovative RTSM solutions that prioritize reliability, flexibility and patient-centric outcomes. The Everest Group PEAK Matrix(R) is a proprietary framework that evaluates providers based on two critical dimensions: market impact and vision and capability. Market impact considers factors such as adoption, portfolio diversity and value delivered to clients, while vision and capability assess strategy, technology innovation, flexibility, engagement models and support services. Endpoint Clinical's leadership position underscores its passion for patients and the privilege of supporting sponsors and CROs across multiple geographies, phases and therapeutic areas. With decades of experience powering thousands of studies, Endpoint delivers RTSM solutions designed for speed, quality and agility, helping to bring life-saving therapies to market. Guided by a customer-first approach, Endpoint provides tailored services and responsive support to ensure every trial runs smoothly and efficiently while continuing to innovate with AI-driven capabilities that enhance decision-making, optimize trial operations and improve outcomes for patients worldwide. "Being recognized as a Leader by Everest Group validates our dedication to bringing innovation in clinical trial operations through our technology, people and exceptional service," said Nagaraja Srivatsan, CEO at Endpoint Clinical. "Our focus remains on providing solutions that combine high quality, speed and agility to ultimately improve outcomes for both patients and sponsors." For more information about Endpoint Clinical's RTSM solutions, visit https://www.endpointclinical.com. To review the report, including details on Endpoint Clinical's Leader status, please visit: https://www.everestgrp.com/report/egr-2025-72-r-7726 About Endpoint Clinical Endpoint Clinical is a trusted clinical trial technology and service partner that delivers reliable RTSM solutions. Endpoint blends seamlessly into clinical trial processes by providing anticipatory and adaptive solutions to proactively mitigate risks. With decades of experience, Endpoint offers a deep understanding of the challenges sponsors and CROs face. Its tech-forward dedication to innovation and high-touch services enables Endpoint to control the controllables and proactively generate speedy, strategic solutions so sponsors and CROs can focus on running seamless clinical trials. SOURCE Endpoint Clinical
RALEIGH, N.C., March 20, 2025 /PRNewswire/ -- Endpoint Clinical ("Endpoint"), a global leader in randomization and trial supply management ("RTSM") solutions and a portfolio company of Arsenal Capital Partners, today announced the appointment of Nagaraja "Sri" Srivatsan as its Chief Executive Officer, effective immediately.Srivatsan, who has served as an Advisor to Endpoint since January 2024 and as Interim CEO since January 2025, has already played a pivotal role in strengthening the company's sales strategy, innovation roadmap, and overall growth trajectory."Sri has demonstrated exceptional leadership, strategic vision, and an unwavering commitment to Endpoint Clinical's mission and stakeholders," said Ray Hill, Chair of the Board of Directors and Operating Partner of Arsenal Capital Partners. "After a comprehensive evaluation, it became clear that he is the right leader to drive Endpoint's next phase of expansion and technological advancement. We are confident in his ability to propel the company forward and create lasting impact for patients, clinical sites, sponsors and partners worldwide."As CEO, Srivatsan will focus on advancing Endpoint's technology suite, expanding its market presence, scaling operations and delivering solutions that enhance and accelerate the clinical trial process."I am honored to lead Endpoint at this exciting time and deeply grateful for the trust placed in me by the Board and our outstanding team," said Srivatsan. "Endpoint is at a pivotal moment in its journey, and I look forward to accelerating our mission of transforming clinical trial management with reliable, innovative, high-quality, and efficient RTSM solutions. Together, we will continue to push the boundaries of what's possible in clinical research, delivering unmatched service and technology to our partners."Before serving as interim CEO, Srivatsan was Senior Vice President and Chief Digital Officer of Research & Development Solutions at IQVIA. He previously held executive roles as Chief Growth Officer at EXL and Venture Partner, Emerging Business Accelerator at Cognizant
Endpoint welcomes Liz Troll as VP, quality.